Glucagon-like peptide 1 content of intestinal tract in adult rats injected with streptozotocin either during neonatal period or 7 d before sacrifice.
Glucagon-like peptide 1 (GLP-1) content of the intestinal tract was recently found to be lower in diabetesprone BioBreeding (BBdp) rats than in the corresponding control animals (BBc rats), a finding compatible with the idea that an inflammatory intestinal state precedes insulitis in these diabetes-prone animals. This study aimed at measuring GLP-1 content of the intestinal tract both in another animal model of type 1 diabetes and in an animal model of type 2 diabetes. GLP-1 content of the jejunum, ileum, colon, and cecum was measured in male and female adult control rats and animals injected with streptozotocin (STZ) either during the neonatal period or 7 d before sacrifice. GLP-1 content of the intestinal tract was higher in type 1 diabetic rats than in control animals. Such was not the case in the type 2 diabetic rats. The findings recorded in the rats injected with STZ either during the neonatal period or later in life indicate that hyperglycemia and/or insulin deficiency do not cause a decrease in GLP-1 content of the intestinal tract. On the contrary, such a content may increase when the glucose intolerance and hypoinsulinemia are sufficiently pronounced, as was the case in the type 1 diabetic rats. These findings are thus compatible with the view that the decreased GLP-1 content of the intestinal tract in BBdp rats may result from intestinal inflammation.
Cancelas
Jesús
J
Fundacíon Jiménez Diaz, Madrid, Spain.
Sancho
Verónica
V
Villanueva-Peñacarrillo
Maria L
ML
Courtois
Philippe
P
Scott
Fraser W
FW
Valverde
Isabel
I
Malaisse
Willy J
WJ
D000818:Animals; D000831:Animals, Newborn; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D002432:Cecum / Q000737:chemistry; D003106:Colon / Q000737:chemistry; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000378:metabolism; D005260:Female; D005934:Glucagon / Q000032:analysis*; D052216:Glucagon-Like Peptide 1; D007082:Ileum / Q000737:chemistry; D007328:Insulin / Q000032:analysis / Q000097:blood; D007422:Intestines / Q000737:chemistry*; D007583:Jejunum / Q000737:chemistry; D008297:Male; D010179:Pancreas / Q000737:chemistry; D010446:Peptide Fragments / Q000032:analysis*; D011498:Protein Precursors / Q000032:analysis*; D011506:Proteins / Q000032:analysis; D051381:Rats; D011913:Rats, Inbred BB; D017208:Rats, Wistar; D013311:Streptozocin / Q000008:administration & dosage*
D001786:Blood Glucose; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; D011506:Proteins; D013311:Streptozocin; D052216:Glucagon-Like Peptide 1; D005934:Glucagon